SEC Form 4 · accession 0001209191-16-147151
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bobby W Sandage Ph.D.
Director
Period of report
Oct 25, 2016
Accepted (ET)
Oct 27, 2016 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $0.58 | Oct 25, 2016 | A | 135,612 | A | — | Oct 25, 2022 | Common Stock | 135,612 | 135,612 | D |
Explanation of responses
- F1Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "Stock Options"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy.
- F2The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Dr. Sandage's continued service on the Board of Directors as of such date.